Truist lowered the firm’s price target on Bristol Myers to $62 from $64 and keeps a Buy rating on the shares after the company reported “strong” Q2 results. The firm said it sees Bristol Myers executing on multiple fronts and see a path forward for growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY: